TAK-632 is a selective pan-RAF inhibitor. It exhibits antitumor activity by inducing RAF dimerization but inhibiting its kinase activity in BRAF- and NRAS-mutated with acquired resistance to BRAF inhibitor in human and mouse melanoma cell.
Dangerous Goods Info:
Nakamura, A., et al.: Cancer Res., 73, 7043 (2013); Okaniwa, M., et al.: J. Med. Chem., 56, 6478 (2013)